Incidence and predictors of understaging in patients with clinical <scp>T</scp> 1 urothelial carcinoma undergoing radical cystectomy
Jacob Ark(Vanderbilt University Medical Center), Sam S. Chang(Memorial Sloan Kettering Cancer Center), Todd M. Morgan(University of Michigan), Michael S. Cookson(University of Oklahoma Health Sciences Center), Daniel A. Barocas(Vanderbilt University Medical Center), Chaochen You(Vanderbilt University Medical Center), Peter E. Clark(Levine Cancer Institute), Joseph A. Smith(King's College London), Kirk A. Keegan(Vanderbilt University Medical Center), Rodney Davis(The University of Texas MD Anderson Cancer Center), Matthew J. Resnick(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center)
Cited by 92
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845